The control of viral latency is a key issue in Epstein-Barr virus (EBV) biology. Overexpression of the immediate-early protein, BZLF1 (Z), is sufficient to disrupt viral latency. the cellular and viral regulation of this gene product is therefore crucial in determining whether virus infection is latent versus productive. The Z protein can be derived from either of two messages: a 1.0 kb message (transcribed from the BZLF1 promoter) making only Z protein, or a 2.8 kb bicistronic message (transcribed from the BRLF1 promoter) which can make both the Z and BRLF1 (R) immediate-early proteins. Disruption of viral latency could potentially be mediated through activation of either the BZLF1 or the BRLF1 promoter. In this grant we propose to identify the cellular transcription factors mediating disruption of viral latency through activation of either the BZLF1 or the BRLF1 promoter and to determine the biological role of the 1.0 kb message versus the 2.8 kb message as a source of Z protein. We have recently found that both the BZLF1 and BRLF1 promoters are bound by the cellular Yin Yang 1 (YY-1) protein as well as an oct-like protein. We have shown that the BRLF1 (but not the BZLF1) promoter is activated by the cellular transcription factor, Sp1. In addition, we have found that the BRLF1 promoter contains binding sites for the zif268 and WT1 transcription factors. In our first specific aim we will determine the exact binding sites of the various transcription factors binding to the BZLF1 and BRLF1 promoters and create site-directed mutations abolishing these sites. In the second specific aim we will examine the functional significance of each of the various transcription factors binding to the BZLF1 and BRLF1 promoters in different cell types. In the third specific aim we will examine the interaction of the Z and R immediate-early proteins with the cellular transcription factors shown to regulate BZLF1 and BRLF1 promoter function. In the fourth specific aim we will determine the role of the 1.0 kb versus the 2.8 kb message as a source of Z protein in various types of EBV infection using PCR analysis. In the final specific aim we will construct mutant viruses in which either the Z or the R proteins have been abolished, or in which the bicistronic nature of the 2.8 kb message has been destroyed, and determine the biological consequences of these mutations. These studies should help to establish the nature of the cellular factors contributing to viral latency and the role of the BZLF1 versus the BRLF1 promoter in the disruption of viral latency.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA058853-03
Application #
2099487
Study Section
Experimental Virology Study Section (EVR)
Project Start
1993-08-01
Project End
1998-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hoebe, Eveline; Wille, Coral; Hagemeier, Stacy et al. (2018) Epstein-Barr Virus Gene BARF1 Expression is Regulated by the Epithelial Differentiation Factor ?Np63? in Undifferentiated Nasopharyngeal Carcinoma. Cancers (Basel) 10:
Kenney, Shannon C; Mertz, Janet E (2014) Regulation of the latent-lytic switch in Epstein-Barr virus. Semin Cancer Biol 26:60-8
Wille, Coral K; Nawandar, Dhananjay M; Panfil, Amanda R et al. (2013) Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J Virol 87:935-50
Raver, Ryan M; Panfil, Amanda R; Hagemeier, Stacy R et al. (2013) The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1. J Virol 87:8053-63
Hoebe, E K; Wille, C; Hopmans, E S et al. (2012) Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation. J Virol 86:11322-32
Robinson, Amanda R; Kwek, Swee Sen; Kenney, Shannon C (2012) The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog 8:e1002516
Hagemeier, Stacy R; Barlow, Elizabeth A; Meng, Qiao et al. (2012) The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol 86:13360-70
Ma, Shi-Dong; Yu, Xianming; Mertz, Janet E et al. (2012) An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 86:7976-87
Ryan, Julie L; Shen, You-Jun; Morgan, Douglas R et al. (2012) Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci 57:1887-98
Shaffer, Donald R; Savoldo, Barbara; Yi, Zhongzhen et al. (2011) T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 117:4304-14

Showing the most recent 10 out of 53 publications